Linvoseltamab for Multiple Myeloma: Results from IMS 2023 With Madhav Dhodapkar, MD

Oncology Data Advisor · Oct 5, 2023 · 6m

At the International Myeloma Society (IMS) 2023 Annual Meeting and Exposition, Dr. Madhav Dhodapkar, Director of the Cancer Center at Emory University, presented the results of the LINKER-MM1 trial of linvoseltamab for relapsed/refractory multiple myeloma. Here, he further delves into the efficacy of linvoseltamab observed in the trial and its projected place in the treatment landscape.